Stockscreener 앱 받기
6.28
5.85%
-0.39
Astria Therapeutics Inc 주식(ATXS)의 최신 뉴스
Can Astria Therapeutics Inc. hit a new high this monthPattern Breakout Prediction for Short Term - Newser
Why Astria Therapeutics Inc. stock attracts strong analyst attentionImmediate Entry Point Prediction Strategy - Newser
How high can Astria Therapeutics Inc. stock goFree Accurate Technical Trend Reversal Picks - Newser
How Astria Therapeutics Inc. stock performs during market volatilityFree Momentum Based Equity Trading Plan - Newser
Is Astria Therapeutics Inc. showing signs of accumulationInvestment Roadmap for High Potential Stocks - Newser
Price action breakdown for Astria Therapeutics Inc.AI-Based Reversal Point Prediction Signal - Newser
Is it time to cut losses on Astria Therapeutics Inc.Daily Profit Watch With Forecast Confidence - Newser
Astria Therapeutics (ATXS) Projected to Post Earnings on Monday - Defense World
Can trapped investors hope for a rebound in Astria Therapeutics Inc.Free Alpha Driven Watchlist With Alerts - Newser
Astria Therapeutics Inc. stock prediction for this weekFree Smart Allocation Stock Pick Insights - Newser
Astria licenses rare disease drug Navenibart to Japan’s Kaken Pharma in $32 M deal - BioSpectrum Asia
Astria Therapeutics Inc. stock momentum explainedAsset Safety Selection Using Quantitative Analysis - Newser
How to build a dashboard for Astria Therapeutics Inc. stockFree Short Term Setup With Predictive Chart - Newser
Astria Therapeutics shares fall 1.15% intraday after being dropped from multiple Russell indices. - AInvest
Astria Therapeutics licenses navenibart rights to Kaken for HAE - Yahoo Finance
What earnings revisions data tells us about Astria Therapeutics Inc.Free Wealth Building Stock Market Ideas - Newser
How to escape a deep drawdown in Astria Therapeutics Inc.Chart Confirmation Setup with ROI Signals - Newser
Astria Therapeutics’ Strategic Advancements and Market Potential: A Buy Recommendation by Joseph Pantginis - TipRanks
Astria Therapeutics: Strategic Partnership and Promising Phase 3 Trial Justify Buy Rating - TipRanks
Astria Therapeutics Strikes Licensing Deal in Japan - MarketScreener
Astria Therapeutics Licenses Japan Rights to Navenibart in $16mln Deal, Kaken Pharmaceutical to Support Phase 3 Trials and Commercialization - AInvest
Astria Therapeutics Licenses Japan Rights To Navenibart In $16 Mln Deal - Nasdaq
Astria Therapeutics Enters Licensing Deal with Kaken - TipRanks
Astria, Kaken ink deal to develop navenibart for HAE in Japan - MarketScreener
ATXS inks $16M navenibart deal with Kaken; runway now into 2028 | ATXS SEC FilingForm 8-K - Stock Titan
Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan - Business Wire
Astria Therapeutics Grants Stock Options to Two New Employees Under Nasdaq Listing Rule 5635(c)(4) - AInvest
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 4, 2025 - BioSpace
Will Astria Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsDaily Pick Forecast with Entry Zones - Newser
What catalysts could drive Astria Therapeutics Inc. stock higher in 2025Achieve impressive returns with smart timing - Jammu Links News
Applying sector rotation models to Astria Therapeutics Inc.Low Risk Stock Selection Strategy Guide - Newser
What is Astria Therapeutics Inc. company’s growth strategyMarket-beating performance - Jammu Links News
What institutional investors are buying Astria Therapeutics Inc. stockDiscover undervalued stocks before they soar - Jammu Links News
What are the technical indicators suggesting about Astria Therapeutics Inc.Real-time trading signals for maximum returns - Jammu Links News
Is Astria Therapeutics Inc. a growth stock or a value stockBuild wealth faster with expert stock selection - Jammu Links News
What is the dividend policy of Astria Therapeutics Inc. stockBuild your wealth with consistent stock growth - Jammu Links News
How many analysts rate Astria Therapeutics Inc. as a “Buy”Consistent triple-digit returns - Jammu Links News
Will Astria Therapeutics Inc. continue its uptrendMulti-Year Investment Performance Summary Report - Newser
0.24%
3.39%
자본화:
|
볼륨(24시간):